Recent 8-K filings for TECH

• May 6, 2026, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 8.01item 9.01 ◈ Earnings Releases

  Bio-Techne Q3 revenue down 2% to $311.4M, adj EPS $0.53; declares $0.08 dividend

  Revenue $311.4M, down 2% reported and organic; GAAP EPS $0.32 (up from $0.14), adjusted EPS $0.53 (down from $0.56).

• February 4, 2026, 6:59 PM ET earnings materiality 0.65 positive item 2.02item 8.01item 9.01

  Bio-Techne Q2 revenue flat at $295.9M; adjusted EPS rises to $0.46 from $0.42

  GAAP EPS of $0.24 vs $0.22; adjusted EPS of $0.46 vs $0.42, both year-over-year increases.

• November 5, 2025, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 5.07item 8.01item 9.01

  Bio-Techne Q1 FY2026 revenue down 1% to $286.6M; adjusted EPS flat $0.42; declares $0.08 dividend

  Revenue $286.6M (-1% YoY); GAAP EPS $0.24 (up from $0.21); adjusted EPS $0.42 (flat).

• August 6, 2025, 7:59 PM ET earnings materiality 0.80 negative item 2.02item 8.01item 9.01

  Bio-Techne Q4 GAAP EPS -$0.11, adjusted EPS $0.53; organic revenue +3%; announces Exosome divestiture

  GAAP EPS loss of $0.11 vs $0.25 profit a year ago; adjusted EPS $0.53 vs $0.49.

• May 7, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 8.01item 9.01

  Bio-Techne Q3 revenue $316.2M (+6% organic), adj EPS $0.56, declares $0.08 dividend and $500M buyback

  Q3 organic revenue +6% to $316.2M; GAAP EPS $0.14 vs $0.31 YoY; adjusted EPS $0.56 vs $0.48 YoY.

• March 4, 2025, 6:59 PM ET litigation materiality 0.75 negative item 5.02item 9.01

  Bio-Techne ordered to pay former CEO $35.98M over option expiration error

  Arbitrator awarded former CEO Charles Kummeth $35.978M for options lost due to administrative error.

• February 5, 2025, 6:59 PM ET earnings materiality 0.65 positive item 2.02item 5.02item 8.01item 9.01 ◈ executive_change

  Bio-Techne Q2 organic revenue +9% to $297M, adjusted EPS $0.42; declares $0.08 dividend

  Q2 organic revenue up 9% to $297.0M; GAAP EPS $0.22 vs $0.17, adjusted EPS $0.42 vs $0.40.

• October 30, 2024, 7:59 PM ET earnings materiality 0.60 positive item 2.02item 5.07item 8.01item 9.01

  Bio-Techne Q1 revenue $289.5M (organic +4%), adj EPS $0.42; declares $0.08 dividend

  Q1 revenue $289.5M, up 5% reported (4% organic); GAAP EPS $0.21 vs $0.31; adjusted EPS $0.42 vs $0.41.

• August 7, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 8.01item 9.01

  Bio-Techne Q4 adjusted EPS $0.49 vs $0.55 YoY; revenue $306.1M (+2%)

  Q4 organic revenue up 1% to $306.1M; FY2024 organic revenue up 1% to $1.2B.

• May 1, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 8.01item 9.01 ◈ Earnings Releases

  Bio-Techne Q3 FY2024: Revenue $303.4M (+2% organic); GAAP EPS $0.31 vs $0.43; declares $0.08 dividend

  Q3 revenue $303.4M (organic +2%, reported +3%); GAAP EPS $0.31 vs $0.43; adjusted EPS $0.48 vs $0.53.

• February 1, 2024, 6:59 PM ET earnings materiality 0.60 negative item 2.02item 8.01item 9.01 ◈ Earnings Releases

  Bio-Techne Q2 organic revenue down 2% to $272.6M; GAAP EPS $0.17 vs $0.31 YoY; declares $0.08 dividend

  Q2 organic revenue declined 2% to $272.6M; reported revenue flat vs prior year.

• January 8, 2024, 6:59 PM ET leadership materiality 0.60 neutral item 5.02item 8.01item 9.01 ◈ executive_change

  Bio-Techne appoints Matthew McManus as President DGS; Kim Kelderman to become CEO Feb 1, 2024

  Matthew McManus appointed President – Diagnostics and Genomics Segment, effective Jan 8, 2024.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.80 · Median 0.60 · Most common event earnings

4 positive 3 negative 9 neutral

source · TECH on sec.gov